F-Star Therapeutics Inc
NASDAQ:FSTX
Intrinsic Value
F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of FSTX.
F-Star Therapeutics Inc's market capitalization is 156.5m USD.
FSTX stock price is 7.12 USD.
FSTX.
FSTX. Open DCF Valuation
FSTX. Open Relative Valuation
FSTX.
FSTX's Revenue has grown by 19% over the past 12 months.
FSTX's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -97% to -83%, and is approaching profitability.
FSTX's ROE (Return on Equity) has significantly increased in the last 3 years from -87% to -61%, and is approaching profitability.
FSTX has negative Operating Income for the last twelve months.
FSTX has negative Net Income for the last twelve months.
FSTX's ROE (Return on Equity) for the past 12 months is negative and is equal to -61%.
FSTX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -83%.
FSTX's Revenue is forecast to fall at a rate of 46% per year over the next 3 years.
FSTX's long-term assets (84m USD) exceed its long-term liabilties (27m USD).
FSTX has negative Free Cash Flow for the last twelve months.
FSTX's short-term assets (50m USD) exceed its short-term liabilties (15m USD).
FSTX's D/E (Debt to Equity) is very low and is equal to 0.15.
FSTX has negative three-year average ROE (Return on Equity): -54%. The company is not efficient at transforming stockholders' equity into net income.
FSTX has negative three-year average ROIC (Return on Invested Capital): -153%. The company is not efficient at using invested capital to generate operating income.
FSTX has negative Net Debt. This means that the company has more cash and short-term investments (36m USD) than debt (9m USD).
FSTX's Altman Z-Score is very low and is equal to -0.82.
FSTX doesn't generate enough operating income (-37m USD) to safely cover interest payments on its debt (1m USD).
Fundamental Analysis
F-Star Therapeutics Inc
Balance Sheet Decomposition
F-Star Therapeutics Inc
| Current Assets | 49.6m |
| Cash & Short-Term Investments | 35.6m |
| Receivables | 8.1m |
| Other Current Assets | 5.9m |
| Non-Current Assets | 34.1m |
| PP&E | 3.4m |
| Intangibles | 30.3m |
| Other Non-Current Assets | 412k |
| Current Liabilities | 14.7m |
| Accounts Payable | 2.5m |
| Accrued Liabilities | 8.6m |
| Other Current Liabilities | 3.6m |
| Non-Current Liabilities | 12.1m |
| Long-Term Debt | 8.5m |
| Other Non-Current Liabilities | 3.6m |
Earnings Waterfall
F-Star Therapeutics Inc
|
Revenue
|
21.2m
USD
|
|
Operating Expenses
|
-57.9m
USD
|
|
Operating Income
|
-36.8m
USD
|
|
Other Expenses
|
-8m
USD
|
|
Net Income
|
-44.7m
USD
|
Free Cash Flow Analysis
F-Star Therapeutics Inc
What is Free Cash Flow?
FSTX Profitability Score
Profitability Due Diligence
F-Star Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
F-Star Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
FSTX Solvency Score
Solvency Due Diligence
F-Star Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
F-Star Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FSTX Price Targets Summary
F-Star Therapeutics Inc
Ownership
FSTX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
FSTX Price
F-Star Therapeutics Inc
| Average Annual Return | -25.93% |
| Standard Deviation of Annual Returns | 65.97% |
| Max Drawdown | -94% |
| Market Capitalization | 156.5m USD |
| Shares Outstanding | 21 981 900 |
| Percentage of Shares Shorted | 5.64% |
Company Profile
F-Star Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. The company employs 84 full-time employees The company went IPO on 2016-05-06. The firm's FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. The company is also developing FS222, FS120 and SB 11285 in Phase I clinical trials in patients with advanced cancers. FS222 is focused on patients with tumors that express low levels of PD-L1 and is a tetravalent, bispecific natural antibody (mAb2) bispecific antibody that is designed to target both the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. FS120 is focused to improve checkpoint inhibitor and chemotherapy outcomes and is a mAb2 bispecific antibody that is designed to bind to and stimulate OX40 and CD137. SB 11285 is focused on improving checkpoint inhibition outcomes as an immunotherapeutic compound for the treatment of selected cancers.
You don't have any saved screeners yet
